HOME >> BIOLOGY >> NEWS
Promising biomarker for melanoma is identified

NYU School of Medicine researchers have identified a potential biomolecular marker for melanoma, the most serious form of skin cancer. In a new study, they report that the marker, a kind of molecular signature, may help identify people with melanoma who have a better prognosis and longer life-expectancy after the cancer is removed.

The study was led by Iman Osman, M.D., and David Polsky, M.D., Ph.D., who collaborated with other researchers from NYU and from Memorial Sloan-Kettering Cancer Center in New York. It will be published in the Dec. 4 issue of the Journal of the National Cancer Institute.

The researchers measured the amount of a molecule called HDM2 in tissue samples of melanoma from patients who were treated and followed at New York University Medical Center from November 1972 through November 1982. The study found that higher levels of the molecule were associated with a better prognosis; namely patients with high levels lived significantly longer after treatment than patients with low levels. And the association was maintained independent of other prognostic indicators, such as tumor thickness.

The difference between the two groups was maintained even ten years after treatment. Some 53 percent of patients with low levels had suffered a recurrence compared with 28 percent of those with high levels, according to the study. Overall, 55 percent of those with low levels had died, compared with 38 percent with high levels of the molecule.

"We think this is a promising biomarker for melanoma," says Dr. Osman, a medical oncologist. "Previously, we had determined that HDM2 was abundant in melanoma, but we didn't understand what this meant for the patient. With this retrospective study, we were able assess whether HDM2 levels at the time of diagnosis could help predict the course of the disease," she says. "The strength of our study is the large number of patients and the long-term follow-up that extends up t
'"/>

Contact: Marjorie Shaffer
Marjorie.Shaffer@med.nyu.edu
212-404-3555
New York University Medical Center and School of Medicine
3-Dec-2002


Page: 1 2 3

Related biology news :

1. Promising hospital anti-infection strategy probably wont work, study shows
2. Promising research: From employment issues to virology
3. Promising new tool shows how dividing cells finish what they start
4. Promising multi-strain HIV vaccine candidate emerges
5. Promising new therapies for deadly form of leukemia
6. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
7. SFU Spin-Off Company To Research Promising Antibacterial Agents
8. SFU Molecular Biologist Pursues Promising New Way To Fight Disease
9. UNC-CH Researchers Develop Promising Heart Research Tool
10. Duke Researchers Call Gene Therapy A Promising Strategy For Sickle Cell Anemia
11. Promising Fatty Acid Research Leads To MS Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/8/2019)... , ... October 07, 2019 , ... The future of ... the genetic level, resulting in people living longer, healthier lives. But it will be ... earth. , Leroy E. Hood, MD, PhD, Chief Strategy Officer and Co-Founder of the ...
(Date:10/3/2019)... ... 02, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... approved clinical trial for stem cell treatment of knee osteoarthritis . The successful enrollment ... a subsidiary of VetStem Biopharma. , PSC CEO, Michael Dale, stated, “We are proud ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem cells (hiPSCs) ... the development and diseases of the human heart, there is an increasing need for ... muscle cells to be clearly and easily recorded. A study released today in STEM ...
Breaking Biology News(10 mins):
(Date:9/17/2019)... ... September 17, 2019 , ... Tucker, a Labrador retriever, was just a puppy ... was limping and lame on his right hip and elbow. At one year of ... “the worst case the vet had seen.” He was prescribed pain medications, both oral ...
(Date:9/17/2019)... ... September 16, 2019 , ... When a lot of researchers ... allow for the complete 3D characterization of tissues through the use of confocal and ... imaging, image analysis and advanced cell culture focused contract research organization and today offers ...
(Date:9/11/2019)... ... September 09, 2019 , ... ... and government agencies, announced that its president and CEO Maryann Gallivan has been ... leaders. , The Forbes Council accepted Gallivan based on the role she and ...
(Date:9/11/2019)... ... September 10, 2019 , ... Catalent, the ... biologics, gene therapies, and consumer health products, today announced that Alex Haig, Senior ... Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18-19, 2019. , On ...
Breaking Biology Technology:
Cached News: